YCYabing Chen

Yabing Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yabing Chen has a total of 203 co-authors. Here are the top co-authors by number of shared publications:

  • Yong Sun

    Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA; Research Department, Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA

    6 shared publications
  • Hui Wu

    Oregon Health and Science University

    5 shared publications
  • Kaiyu Yuan

    Department of Pathology, University of Alabama at Birmingham, Birmingham, USA

    5 shared publications
  • Tong Zhou

    Department of Medicine, University of Alabama at Birmingham, Birmingham, USA

    5 shared publications
  • Elena Aikawa

    Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women's Hospital, Harvard Medical School , 3 Blackfan Street, 17th Floor, Boston, MA 02115

    3 shared publications
  • Fei Xu

    Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

    3 shared publications

Latest Publications

  • Inhibition of mitochondrial permeability transition selectively suppresses thrombogenic platelet procoagulant activity

    by Yiheng Zhang, Jordan Sandler, Osamede Clinton Owegie, Xu Zhang, Vrishank Shivaprakash, Jack Kurth, Yong Sun, Mayu Morita, Raquel Mote, Neva Scott, et al.

    Platelets support coagulation by externalizing phosphatidylserine (PS), creating a catalytic surface for thrombin generation and fibrin formation. Although platelet PS exposure is required for hemostasis, excessive procoagulant platelet activity drives thrombosis. Sustained calcium influx after strong agonist stimulation promotes mitochondrial permeability transition pore (mPTP) opening, mitochondrial depolarization and calcium amplification that commit platelets to PS-high procoagulant states. Existing approaches to suppress this pathway are limited by the hemostatic requirement for platelet PS exposure and pleiotropic effects of cyclophilin-targeting agents. Here, we use a series of newly developed cyclophilin D-independent small molecule mPTP inhibitors to define how mPTP opening regulates procoagulant platelet activity. Under GPVI/PAR-driven procoagulant conditions, MC63, TR001 and TR002 preserved mitochondrial membrane potential, prevented intracellular calcium overload and reduced PS/P-selectin-positive platelets, microparticle release and membrane blebbing, while preserving agonist-induced calcium mobilization, secretion, integrin activation, aggregation, F-actin assembly and clot retraction. Mechanistically, mPTP inhibition limited calcium-dependent phosphatase, protease and mitochondrial activities associated with procoagulant platelet conversion. MC63, TR001 and TR002 reduced platelet-dependent thrombin generation and fibrin formation without affecting platelet-independent thrombin activity. In whole blood perfused over collagen, mPTP inhibitors reduced PS-positive platelets within thrombi without impairing platelet accumulation. In vivo, mPTP inhibitors decreased platelet and fibrin accumulation after laser-induced arteriolar injury but did not prolong tail bleeding alone or in combination with acetylsalicylic acid. Together, these findings identify mPTP opening as a druggable checkpoint for platelet procoagulant commitment and support mPTP inhibition as an antithrombotic strategy that may preserve hemostasis.

  • Open Access

    Medin-Induced Pro-inflammatory and Prothrombotic Activation of Coronary Artery Endothelial Cells: A Potential Novel Mediator Linking Aging and Atherosclerosis

    by Kaleb Morrow, Nina Karamanova, Randy Woltjer, Victoria Krajbich, Jingmin Shu, Ming Li, Chengyun Tang, Alana Maerivoet, Jillian Madine, Yabing Chen, et al.

    Background: Age is the most important risk factor for coronary artery disease (CAD) independent of traditional risk factors. Aging induces classic pro-inflammatory and prothrombotic vascular phenotypic changes whose molecular mediators remain poorly understood. Medin is a common cleavage product protein that accumulates in vasculature with aging and shown to cause endothelial dysfunction. Its role in CAD is unknown. The study aimed to evaluate the effects of medin on human coronary artery endothelial cell (HCAEC) pro-inflammatory and prothrombotic activation and establish the relationship between medin and coronary atherosclerosis in human decedents. Methods: HCAECs were exposed to physiologic dose of medin (5 µM) for 20 hours and ribonucleic acid sequencing (RNAseq) with signaling pathway analyses and reverse transcription polymerase chain reaction of select pro-inflammatory and prothrombotic genes performed. Corresponding protein expression was measured by Western blot or enzyme linked immunosorbent assay in HCAECs exposed to medin (5 µM) without or with nuclear factor-κB (NFκB) inhibitor RO106-9920 (10 µM). Coronary arteries from 40 deceased individuals underwent immunohistochemistry and medin and plaque burden were quantified and their relationship evaluated. Results: RNAseq showed predominant pro-inflammatory gene expression changes induced by medin. HCAECs treated with medin showed increased phosphorylated NFκB, elevated protein expression of interleukin (IL)-6, IL-8, monocyte chemotactic protein (MCP)-1, intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1 and plasminogen activator inhibitor (PAI)-1 and reduced protein expression of thrombomodulin; these changes were reversed by RO106-9920 co-treatment. In human tissues, coronary artery medin strongly correlated with plaque burden (R=0.76, p<0.0001) and coronary macrophage content (R=0.72, p<0.0001). Coronary arteries from decedents with myocardial infarction had higher medin than those without (5.53±2.67% versus 0.02±0.02%, p=0.0005). Conclusions: Medin induced NFκB-mediated endothelial cell pro-inflammatory and prothrombotic activation and was strongly associated with coronary plaque burden and inflammation. Medin is a novel candidate mediator linking aging and coronary atherosclerosis.

  • Phosphoproteomics in Vascular Biology and Disease: Illuminating Signaling in the Vessel

    by Kayleigh Voos, Ming He, Gina Many, Yabing Chen, Wei-Jun Qian

    Phosphoregulatory events underlie vascular responses to environmental and pathological stimuli, regulate hemostasis and thrombosis, and drive vascular remodeling in health and disease. Consequently, defining phosphorylation-dependent signaling networks in vascular physiology and pathology has enabled biomarker discovery and informed therapeutic interventions. Advances in mass spectrometry–based phosphoproteomics have enabled accurate and high-resolution mapping of dynamic phosphorylation events at the systems level, providing comprehensive mechanistic insights into vascular signaling and pathology. In this review, we contextualize phosphorylation in the vascular niche and summarize the current state of phosphoproteomics in vascular research, highlighting experimental design considerations, technological advances, quantification strategies, and data analysis approaches to uncover biological insights from large-scale phosphoproteomic data sets. Finally, we discuss recent discoveries in vascular signaling and disease, along with current challenges and emerging directions for applying phosphoproteomics to critical questions in vascular biology.

  • Bmal1 Regulates Vascular Calcification via Noncanonical Circadian Pathway—Brief Report

    by Ming He, Yong Sun, Chengyun Tang, Fengyuan Huang, Zhehao Zhu, Sujin Lee, Erandi Velazquez-Miranda, Wonmo Ahn, Rajeev Malhotra, Zechen Chong, et al.

    BACKGROUND: Vascular calcification is a major contributor to cardiovascular morbidity and mortality in diabetes and is driven in part by osteogenic reprogramming of vascular smooth muscle cells (SMCs). Diabetes is also associated with circadian rhythm disruption; however, how circadian regulators contribute to vascular calcification remains poorly understood. We investigated the role of the core circadian protein Bmal1 (basic helix-loop-helix ARNT-like protein 1) in diabetes-associated vascular calcification. METHODS: Bmal1 expression was examined in diabetic mouse aortas, human diabetic arterial tissues, and vascular SMCs exposed to high glucose. SMC-specific Bmal1 knockout mice were generated and subjected to low-dose streptozotocin-induced diabetes. Vascular calcification and stiffness were assessed by calcium staining and quantification, and pulse wave velocity. RNA sequencing, chromatin immunoprecipitation, luciferase reporter assay, and clustered regularly interspaced short palindromic repeats-clustered regularly interspaced short palindromic repeat–associated 9–mediated genome editing were used to define Bmal1-regulated molecular mechanisms. RESULTS: Bmal1, but not other circadian regulators, was selectively upregulated in diabetic arteries and vascular SMCs under hyperglycemic conditions. SMC-specific deletion of Bmal1 markedly attenuated diabetes-induced vascular calcification, reduced aortic stiffness, and suppressed osteogenic gene expression in vivo and in vitro. RNA-sequencing analysis revealed enrichment of Bmal1-dependent genes involved in osteogenic differentiation and extracellular matrix organization. Mechanistically, Bmal1 directly binds to an E-box motif in the Runx2 (Runt-related transcription factor 2) promoter, enhancing Runx2 transcription independently of canonical circadian pathways. Disruption of Bmal1 binding to the Runx2 promoter abolished Bmal1-induced Runx2 expression. CONCLUSIONS: Our findings identify Bmal1 as a key mediator of diabetes-induced vascular calcification through direct transcriptional regulation of Runx2 via a noncanonical circadian mechanism. These results reveal a previously unrecognized pathogenic role for Bmal1 in vascular disease and suggest that targeting dysregulated circadian factors may represent a novel therapeutic strategy for preventing vascular calcification in diabetes.


  • Peripheral Vascular Calcification

    by Sujin Lee, Jenny Woo, Yabing Chen, Shipra Arya, Matthew Allison

    Peripheral artery disease commonly refers to diffuse atherothrombotic disease of the arteries supplying the legs. Peripheral artery disease has been relatively understudied and has not been subject to the same intensive scrutiny and research that characterizes coronary artery disease. Moreover, the diagnosis of peripheral artery disease can be complicated by the presence of arterial calcification. Here, we provide a brief report on the current understanding of peripheral vascular calcification to include the following sections: basic mechanisms, anatomic distribution of arterial calcification, manifestations, risk factors, measurement of peripheral calcification, nonsurgical treatments, and surgical interventions.


  • Open Access

    A Novel FNDC1-NAMPT-NAD axis is Implicated in Small and Large-vessel Arterial Disease and Drives Vascular Calcification

    by Sujin Lee, Yugene Guo, Lova Prasadareddy Kajuluri, Kangsan Roh, Kuldeep Singh, Wanlin Jiang, Elizabeth Moore, Helena Tattersfield, Katrina Ostrom, Claire Birchenough, et al.

    Vascular calcification represents a convergent pathological feature of diverse cardiovascular diseases, yet the upstream molecular programs orchestrating this process remain poorly defined. Here, we uncover fibronectin type III domain-containing 1 (FNDC1) as a previously unrecognized regulator of vascular calcification across both microvascular and macrovascular beds. Integrative transcriptomic profiling of human calciphylaxis lesions and atherosclerotic coronaries identified FNDC1 as one of the most significantly upregulated genes. In primary human vascular smooth muscle cells, FNDC1 drove osteogenic phenotype switch and vascular calcification through activation of PI3K/AKT signaling and metabolic reprogramming. Mechanistically, FNDC1 directly binds to nicotinamide phosphoribosyltransferase (NAMPT) resulting in elevated intracellular NAD⁺ levels, thus coupling vascular signaling to control of NAD⁺ biosynthesis. In murine models, genetic deletion of Fndc1 or pharmacologic inhibition of NAMPT suppressed arterial calcification and prolonged survival. Clinically, circulating FNDC1 levels were elevated in patients with both calciphylaxis and coronary artery disease and independently predicted cardiovascular risk in 42,687 UK Biobank participants. Together, these findings establish FNDC1 as a central mediator of vascular pathology and highlight the FNDC1– NAMPT-NAD + axis as a promising target for therapeutic intervention.

  • Honoring the Life and Legacy of Dr David A. Dichek

    by Elena Aikawa, Matthew A. Allison, Luisa Iruela Arispe, Michelle P. Bendeck, Yabing Chen, Elizabeth E. Gardiner, Jonathan Golledge, Katsue Suzuki-Inoue, Federica Marelli-Berg, Janet T. Powell, et al.

  • Top Cited Papers

    Phosphate in Cardiovascular Disease: From New Insights Into Molecular Mechanisms to Clinical Implications

    by Mandy E. Turner, Laurent Beck, Kathleen M. Hill Gallant, Yabing Chen, Orson W. Moe, Makoto Kuro-O, Sharon M. Moe, Elena Aikawa

    Hyperphosphatemia is a common feature in patients with impaired kidney function and is associated with increased risk of cardiovascular disease. This phenomenon extends to the general population, whereby elevations of serum phosphate within the normal range increase risk; however, the mechanism by which this occurs is multifaceted, and many aspects are poorly understood. Less than 1% of total body phosphate is found in the circulation and extracellular space, and its regulation involves multiple organ cross talk and hormones to coordinate absorption from the small intestine and excretion by the kidneys. For phosphate to be regulated, it must be sensed. While mostly enigmatic, various phosphate sensors have been elucidated in recent years. Phosphate in the circulation can be buffered, either through regulated exchange between extracellular and cellular spaces or through chelation by circulating proteins (ie, fetuin-A) to form calciprotein particles, which in themselves serve a function for bulk mineral transport and signaling. Either through direct signaling or through mediators like hormones, calciprotein particles, or calcifying extracellular vesicles, phosphate can induce various cardiovascular disease pathologies: most notably, ectopic cardiovascular calcification but also left ventricular hypertrophy, as well as bone and kidney diseases, which then propagate phosphate dysregulation further. Therapies targeting phosphate have mostly focused on intestinal binding, of which appreciation and understanding of paracellular transport has greatly advanced the field. However, pharmacotherapies that target cardiovascular consequences of phosphate directly, such as vascular calcification, are still an area of great unmet medical need.